A Study of the Safety and Antiretroviral Activity of 3BNC117

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

February 28, 2018

Study Completion Date

April 30, 2018

Conditions
HIV-1 Infection
Interventions
DRUG

3BNC117

3BNC117 infusions

OTHER

Antiretroviral Treatment Interruption

Antiretroviral therapy will be discontinued 2 days after the third 3BNC117 infusion, at week 24, and resumed at week 36.

Trial Locations (2)

10065

The Rockefeller University, New York

Weill Cornel Medical Center, New York

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Bill and Melinda Gates Foundation

OTHER

collaborator

Weill Medical College of Cornell University

OTHER

collaborator

Montefiore Medical Center

OTHER

lead

Rockefeller University

OTHER

NCT02588586 - A Study of the Safety and Antiretroviral Activity of 3BNC117 | Biotech Hunter | Biotech Hunter